➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Johnson and Johnson
Harvard Business School
McKinsey
Medtronic

Last Updated: September 19, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TAFLUPROST

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Tafluprost

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00596791 ↗ Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops Completed Santen Oy Phase 3 2008-01-01 The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye drops.
NCT00918346 ↗ Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation Completed Santen Oy Phase 3 2005-09-01 The objective of this study is to investigate the pharmacodynamics (as expressed in intraocular pressure [IOP]) of two formulations of tafluprost 0.0015% eyedrops (preserved and unpreserved) in patients with open-angle glaucoma or ocular hypertension. The primary aim of this study is to show that IOP reduction between the two formulations is equivalent at the end of the 4 week treatment period.
NCT00966940 ↗ Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed Alcon Research Phase 4 2009-09-01 The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tafluprost

Condition Name

Condition Name for Tafluprost
Intervention Trials
Ocular Hypertension 17
Glaucoma 11
Open-Angle Glaucoma 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tafluprost
Intervention Trials
Glaucoma 26
Ocular Hypertension 20
Glaucoma, Open-Angle 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tafluprost

Trials by Country

Trials by Country for Tafluprost
Location Trials
United States 8
Finland 5
Italy 3
Austria 3
Greece 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tafluprost
Location Trials
California 2
Pennsylvania 1
Texas 1
Ohio 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tafluprost

Clinical Trial Phase

Clinical Trial Phase for Tafluprost
Clinical Trial Phase Trials
Phase 4 12
Phase 3 10
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tafluprost
Clinical Trial Phase Trials
Completed 21
Recruiting 4
Unknown status 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tafluprost

Sponsor Name

Sponsor Name for Tafluprost
Sponsor Trials
Santen Oy 8
Aristotle University Of Thessaloniki 3
Santen Pharmaceutical Co., Ltd. 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tafluprost
Sponsor Trials
Industry 19
Other 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Boehringer Ingelheim
Johnson and Johnson
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.